Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2018

01-02-2018 | Original Paper

Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells

Authors: Trang H. Luu, Jean-Marie Bard, Delphine Carbonnelle, Chloé Chaillou, Jean-Michel Huvelin, Christine Bobin-Dubigeon, Hassan Nazih

Published in: Cellular Oncology | Issue 1/2018

Login to get access

Abstract

Background

It has amply been documented that mammary tumor cells may exhibit an increased lipogenesis. Biliary acids are currently recognized as signaling molecules in the intestine, in addition to their classical roles in the digestion and absorption of lipids. The aim of our study was to evaluate the impact of lithocholic acid (LCA) on the lipogenesis of breast cancer cells. The putative cytotoxic effects of LCA on these cells were also examined.

Methods

The effects of LCA on breast cancer-derived MCF-7 and MDA-MB-231 cells were studied using MTT viability assays, Annexin-FITC and Akt phosphorylation assays to evaluate anti-proliferative and pro-apoptotic properties, qRT-PCR and Western blotting assays to assess the expression of the bile acid receptor TGR5 and the estrogen receptor ERα, and genes and proteins involved in apoptosis (Bax, Bcl-2, p53) and lipogenesis (SREBP-1c, FASN, ACACA). Intracellular lipid droplets were visualized using Oil Red O staining.

Results

We found that LCA induces TGR5 expression and exhibits anti-proliferative and pro-apoptotic effects in MCF-7 and MDA-MB-231 cells. Also, an increase in pro-apoptotic p53 protein expression and a decrease in anti-apoptotic Bcl-2 protein expression were observed after LCA treatment of MCF-7 cells. In addition, we found that LCA reduced Akt phosphorylation in MCF-7 cells, but not in MDA-MB-231 cells. We also noted that LCA reduced the expression of SREBP-1c, FASN and ACACA in both breast cancer-derived cell lines and that cells treated with LCA contained low numbers of lipid droplets compared to untreated control cells. Finally, a decrease in ERα expression was observed in MCF-7 cells treated with LCA.

Conclusions

Our data suggest a potential therapeutic role of lithocholic acid in breast cancer cells through a reversion of lipid metabolism deregulation.
Literature
1.
E. Robles-Escajeda, U. Das, N.M. Ortega, K. Parra, G. Francia, J.R. Dimmock, A. Varela-Ramirez, R.J. Aguilera, A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell. Oncol. 39, 265–277 (2016)CrossRef
2.
R. Sharma, R. Sharma, T.P. Khaket, C. Dutta, B. Chakraborty, T.K. Mukherjee, Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. Cell. Oncol. 40, 199–208 (2017)CrossRef
3.
S. Beloribi-Djefaflia, S. Vasseur, F. Guillaumond, Lipid metabolic reprogramming in cancer cells. Oncogenesis 5, 1–10 (2016)CrossRef
4.
J.A. Menendez, R. Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777 (2007)CrossRefPubMed
5.
J.A. Menendez, R. Lupu, Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells. Oncogenesis 6, 1–11 (2017)CrossRef
6.
J.M. Harvey, G.M. Clark, C.K. Osborne, D.C. Allred, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474–1481 (1999)CrossRefPubMed
7.
P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, B. Staels, Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147–191 (2009)CrossRefPubMed
8.
9.
B.W. Katona, S. Anant, D.F. Covey, W.F. Stenson, Characterization of enantiomeric bile acid-induced apoptosis in colon cancer cell lines. J. Biol. Chem. 284, 3354–3564 (2009)CrossRefPubMedPubMedCentral
10.
A.A. Goldberg, A. Beach, G.F. Davies, T.A. Harkness, A. Leblanc, V.I. Titorenko, Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget 2, 761–782 (2011)CrossRefPubMedPubMedCentral
11.
A.A. Goldberg, V.I. Titorenko, A. Beach, J.T. Sanderson, Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells. Peer J. 1, e122 (2013)CrossRefPubMedPubMedCentral
12.
A.A. Goldberg, V.R. Richard, P. Kyryakov, S.D. Bourque, A. Beach, M.T. Burstein, A. Glebov, O. Koupaki, T. Boukh-Viner, C. Gregg, M. Juneau, A.M. English, D.Y. Thomas, V.I. Titorenko, Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes. Aging 2, 393–414 (2010)CrossRefPubMedPubMedCentral
13.
V. Sepe, B. Renga, C. Festa, C. Finamore, D. Masullo, A. Carino, S. Cipriani, E. Distrutti, S. Fiorucci, A. Zampella, Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity. Steroids 105, 59–67 (2015)CrossRefPubMed
14.
A. Kawaguchi, H. Tomoda, S. Nozoe, S. Omura, S. Okuda, Mechanism of action of cerulenin on fatty acid synthetase. Effect of cerulenin on iodoacetamide-induced malonyl-CoA decarboxylase activity. J. Biochem. 92, 7–12 (1982)PubMed
15.
H. Duboc, Y. Taché, A.F. Hofmann, The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig. Liver Dis. 46, 302–312 (2014)CrossRefPubMed
16.
H. Sato, A. Macchiarulo, C. Thomas, A. Gioiello, M. Une, A.F. Hofmann, R. Saladin, K. Schoonjans, R. Pellicciari, J. Auwerx, Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure−activity relationships, and molecular modeling studies. J. Med. Chem. 51, 1831–1841 (2008)CrossRefPubMed
17.
Y. Kawamata, R. Fujii, M. Hosoya, M. Harada, H. Yoshida, M. Miwa, S. Fukusumi, Y. Habata, T. Itoh, Y. Shintani, S. Hinuma, Y. Fujisawa, M. Fujino, A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435–9440 (2003)CrossRefPubMed
18.
T.W. Pols, L.G. Noriega, M. Nomura, J. Auwerx, K. Schoonjans, The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol. 54, 1263–1272 (2011)CrossRefPubMed
19.
20.
C.C. Harris, Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl. Cancer Inst. 88, 1442–1455 (1996)CrossRefPubMed
21.
H.A. Giebler, I. Lemasson, J.K. Nyborg, p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation. Mol. Cell Biol. 20, 4849–4858 (2000)CrossRefPubMedPubMedCentral
22.
T. Arnould, S. Vankoningsloo, P. Renard, A. Houbion, N. Ninane, C. Demazy, J. Remacle, M. Raes, CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. EMBO J. 21, 53–63 (2002)CrossRefPubMedPubMedCentral
23.
S. Cory, D.C.S. Huang, J.M. Adams, The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590–8607 (2003)CrossRefPubMed
24.
Rahimi A, Lee YY, Abdella H, Doerflinger M, Gangoda L, Srivastava R, Xiao K, Ekert PG, Puthalakath H. Role of p53 in cAMP/PKA pathway mediated apoptosis. Apoptosis 18, 1492–1499 (2013)
25.
S.M. Vogel, M.R. Bauer, A.C. Joerger, R. Wilcken, T. Brandt, D.B. Veprintsev, T.J. Rutherford, A.R. Fersht, F.M. Boeckler, Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Proc. Natl. Acad. Sci. USA 109, 16906–16910 (2012)CrossRefPubMedPubMedCentral
26.
M. Yoeli-Lerner, A. Toker, Akt/PKB signaling in cancer: A function in cell motility and invasion. Cell Cycle 5, 603–605 (2006)CrossRefPubMed
27.
B.S. Tan, K.H. Tiong, H.L. Choo, F.F. Chung, L.W. Hii, S.H. Tan, I.K. Yap, S. Pani, N.T. Khor, S.F. Wong, R. Rosli, S.K. Cheong, C.O. Leong, Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 6, e1826 (2015)CrossRefPubMedPubMedCentral
28.
C.R. Loehberg, P.L. Strissel, R. Dittrich, R. Strick, J. Dittmer, A. Dittmer, B. Fabry, W.A. Kalender, T. Koch, D.L. Wachter, N. Groh, A. Polier, I. Brandt, L. Lotz, I. Hoffmann, F. Koppitz, S. Oeser, A. Mueller, P.A. Fasching, M.P. Lux, M.W. Beckmann, M.G. Schrauder, Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. Biochem. Pharmacol. 83, 480–488 (2012)CrossRefPubMed
29.
A. Astanehe, D. Arenillas, W.W. Wasserman, P.C. Leung, S.E. Dunn, B.R. Davies, G.B. Mills, N. Auersperg, Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J. Cell Sci. 121, 664–674 (2008)CrossRefPubMed
30.
M. Agostini, L.Y. Almeida, D.C. Bastos, R.M. Ortega, F.S. Moreira, F. Seguin, K.G. Zecchin, H.F. Raposo, H.C. Oliveira, N.D. Amoêdo, T. Salo, R.D. Coletta, E. Graner, The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. Mol. Cancer Ther. 13, 585–595 (2014)CrossRefPubMed
31.
B. Corominas-Faja, E. Cuyàs, J. Gumuzio, J. Bosch-Barrera, O. Leis, Á.G. Martin, J.A. Menendez, Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget 5, 8306–8316 (2014)CrossRefPubMedPubMedCentral
32.
R. Singh, V. Yadav, S. Kumar, N. Saini, MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci. Rep. 5, 1–15 (2015)
33.
M. Lu, J.Y. Shyy, Sterol regulatory element-binding protein 1 is negatively modulated by PKA phosphorylation. Am. J. Physiol. Cell Physiol. 290, C1477–C1486 (2006)CrossRefPubMed
34.
T. Yamamoto, H. Shimano, N. Inoue, Y. Nakagawa, T. Matsuzaka, A. Takahashi, N. Yahagi, H. Sone, H. Suzuki, H. Toyoshima, N. Yamada, Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J. Biol. Chem. 282, 11687–11695 (2007)CrossRefPubMed
35.
36.
P.T. Bozza, J.P. Viola, Lipid droplets in inflammation and cancer. Prostaglandins Leukot. Essent. Fatty Acids 82, 243–250 (2010)CrossRefPubMed
37.
L. Tirinato, C. Liberale, S. Di Franco, P. Candeloro, A. Benfante, R. La Rocca, L. Potze, R. Marotta, R. Ruffilli, V.P. Rajamanickam, M. Malerba, F. De Angelis, A. Falqui, E. Carbone, M. Todaro, J.P. Medema, G. Stassi, E. Di Fabrizio, Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells 33, 35–44 (2015)CrossRefPubMed
38.
H. Abramczyk, J. Surmacki, M. Kopec, A.K. Olejnik, K. Lubecka-Pietruszewska, K. Fabianowska-Majewska, The role of lipid droplets and adipocytes in cancer. Raman imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to adipocytes in cancerous human breast tissue. Analyst 140, 2224–2235 (2015)CrossRefPubMed
39.
G. Pérez-Tenorio, O. Stal, Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Brit. J. Cancer 86, 540–545 (2002)CrossRefPubMedPubMedCentral
40.
O. Stal, G. Pérez-Tenorio, L. Akerberg, B. Olsson, B. Nordenskjöld, L. Skoog, L.E. Rutqvist, Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5, R37–R44 (2003)CrossRefPubMedPubMedCentral
41.
J. Bostner, E. Karlsson, M.J. Pandiyan, H. Westman, L. Skoog, T. Fornander, B. Nordenskjöld, O. Stal, Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res. Treat. 137, 397–406 (2013)CrossRefPubMed
42.
R.A. Campbell, P. Bhat-Nakshatri, N.M. Patel, D. Constantinidou, S. Ali, H. Nakshatri, Phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817–9824 (2001)CrossRefPubMed
43.
A. Belkaid, S.R. Duguay, R.J. Ouellette, M.E. Surette, 17β-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells. BMC Cancer 15, 1–14 (2015)CrossRef
44.
M.J. Duffy, Estrogen receptors: Role in breast cancer. Crit. Rev. Clin. Lab. Sci. 43, 325–347 (2006)CrossRefPubMed
Metadata
Title
Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells
Authors
Trang H. Luu
Jean-Marie Bard
Delphine Carbonnelle
Chloé Chaillou
Jean-Michel Huvelin
Christine Bobin-Dubigeon
Hassan Nazih
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0353-5

Other articles of this Issue 1/2018

Cellular Oncology 1/2018 Go to the issue

Original Paper

Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species

Letter to the Editor

Metabolic iodine and tumours

Original Paper

Glycogen synthase kinase-3β mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion

Original Paper

Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma

Original Paper

Memory CD4+ T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells

Report

Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits